CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners.

宾夕法尼亚州康肖霍肯（商业新闻短讯）--Cencora，Inc.（纽约证券交易所代码：COR）今天宣布，它已达成最终协议，从Webster Equity Partners收购Retina Consultants of America（“RCA”），这是一家领先的视网膜专家管理服务组织（MSO）。

“The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty,” said Bob Mauch, President & CEO of Cencora. “With a compelling value proposition for physicians, an impressive leadership team and strong clinical research capabilities, RCA is well-positioned at the forefront of retinal care.

Cencora总裁兼首席执行官鲍勃·莫赫（BobMauch）表示：“收购RCA将使Cencora在高增长领域扩大与社区提供商的关系，并巩固我们在专业领域的领导地位。”。“RCA拥有令人信服的医生价值主张、令人印象深刻的领导团队和强大的临床研究能力，在视网膜护理领域处于领先地位。

We intend to use our leading operational infrastructure to help RCA enhance the provider experience, drive innovative new research and create better outcomes for patients. Following our recent investment in OneOncology, the addition of RCA will allow us to expand our MSO solutions and drive differentiated value across the healthcare system for manufacturers, providers and patients.”.

我们打算利用我们领先的运营基础设施，帮助RCA提高提供者的体验，推动创新的新研究，并为患者创造更好的结果。随着我们最近对OneOncology的投资，RCA的加入将使我们能够扩展MSO解决方案，并为制造商，提供者和患者在整个医疗保健系统中创造差异化价值。”

“We are pleased to enter our next phase of growth with the support of a leading global pharmaceutical solutions organization,” said Robby Grabow, Chief Executive Officer of RCA. “With additional resources to support the continued execution of our growth strategy, we will be better positioned to continue expanding our physician network and enhancing the quality of care we provide.”.

RCA首席执行官罗比·格拉博（RobbyGrabow）表示：“我们很高兴在全球领先的制药解决方案组织的支持下进入下一个增长阶段。”。“有了额外的资源来支持我们继续执行增长战略，我们将能够更好地继续扩大我们的医生网络，提高我们提供的护理质量。”

“The ability to become a part of Cencora and its purpose-driven culture, will further advance RCA’s mission of saving sight and improving the lives of our patients and communities we serve through innovation,” said David Brown, MD, Co-Chair of RCA’s Medical Leadership Board. “Our cultural alignment and shared focus on driving innovation will allow us to unlock new opportunities together and advance the caliber of retina care.”.

RCA医疗领导委员会联合主席DavidBrown医学博士说：“成为Cencora的一部分及其目标驱动文化的能力，将进一步推进RCA的使命，即通过创新挽救视力，改善我们所服务的患者和社区的生活。”。“我们的文化一致性和对推动创新的共同关注将使我们能够共同开启新的机会，并提高视网膜护理的水平。”

The proposed transaction will build on Cencora’s key strategic imperatives and areas of focus by:

拟议交易将以Cencora的关键战略要务和重点领域为基础，通过：

Adding a leader in the community provider space to Cencora: RCA is the leading MSO in the retina space and a trusted healthcare provider. RCA’s nearly 300 retina specialists across 23 states provide high-quality care to patients with physicians conducting over 2 million visits annually.

为Cencora增加了社区提供者领域的领导者：RCA是视网膜领域的领先MSO和值得信赖的医疗保健提供者。RCA在23个州的近300名视网膜专家为患者提供高质量的护理，医生每年进行200多万次就诊。

Expanding Cencora’s leadership in Specialty: As the specialty landscape continues to evolve, providers are increasingly seeking partners to assist with managing their practices while retaining their autonomy and patient-centric approach. The addition of RCA will add to Cencora’s capabilities in Specialty and expand its MSO business, broadening physician and manufacturer relationships as well as Cencora’s value proposition to all its stakeholders..

扩大Cencora在专业领域的领导地位：随着专业领域的不断发展，供应商越来越多地寻求合作伙伴来帮助管理他们的实践，同时保留他们的自主性和以患者为中心的方法。RCA的加入将增加Cencora的专业能力，扩大其MSO业务，扩大医生和制造商的关系，以及Cencora对所有利益相关者的价值主张。

Investing in innovation and contributing to Rx outcomes: RCA has an impressive clinical track record and operates a premier clinical research network with 40 clinical trial sites spanning Phases I-IV and 400 dedicated full-time research employees. Cencora expects to use its suite of manufacturer services to enhance RCA’s research program and outcomes, maintaining its position as a partner of choice to pharmaceutical innovators in the retina space..

投资于创新并为Rx成果做出贡献：RCA拥有令人印象深刻的临床记录，并拥有一流的临床研究网络，拥有40个跨越I-IV期的临床试验地点和400名专职研究人员。Cencora希望利用其一套制造商服务来增强RCA的研究计划和成果，保持其作为视网膜领域药物创新者首选合作伙伴的地位。

Transaction Details

交易详细信息

Cencora will acquire RCA for approximately $4.6 billion in cash, subject to a customary working capital and net-debt adjustment. RCA’s affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain predefined business objectives..

Cencora将以大约46亿美元的现金收购RCA，但须按惯例进行营运资本和净债务调整。RCA的附属机构、医生和管理层将保留RCA的少数股权，Cencora在交割时持有RCA约85%的所有权。此外，Cencora可能会在2027财年和2028财年支付总计5亿美元的或有对价，前提是成功完成某些预定义的业务目标。

The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.

该交易须符合惯例成交条件，包括收到所需的监管批准。

Upon closing, the acquisition of RCA is expected to be approximately $0.35 accretive, net of estimated financing costs, to Cencora’s adjusted diluted EPS (a non-GAAP financial measure defined herein) for its first twelve months. Cencora plans to fund the transaction through a combination of existing cash on hand and new debt financing.

交易结束后，预计RCA的收购将在头十二个月内增加约0.35美元，扣除估计的融资成本，达到Cencora调整后的稀释每股收益（此处定义的非GAAP财务指标）。Cencora计划通过现有库存现金和新债务融资的组合为交易提供资金。

Cencora’s fiscal year 2025 guidance does not currently include the impact of the RCA acquisition, which will be incorporated into expectations following the transaction close..

Cencora 2025财年指南目前不包括RCA收购的影响，交易结束后将纳入预期。

“Cencora is committed to maintaining its strong investment grade credit rating and will prioritize de-leveraging in the years following transaction close,” said Jim Cleary, EVP & Chief Financial Officer.

执行副总裁兼首席财务官吉姆·克利里（JimCleary）表示：“Cencora致力于维持其强大的投资级信用评级，并将在交易结束后的几年内优先考虑去杠杆化。”

Advisors

顾问

Lazard is serving as exclusive financial advisor, and Freshfields LLP, Sidley Austin LLP and Morgan, Lewis & Bockius LLP are serving as legal advisors to Cencora. Goldman Sachs & Co. LLC and Rothschild & Co are serving as financial advisors, and Goodwin Procter LLP and ReedSmith LLP are serving as legal advisors to RCA..

Lazard担任独家财务顾问，Freshfields LLP、Sidley Austin LLP和Morgan、Lewis&Bockius LLP担任Cencora的法律顾问。高盛公司（Goldman Sachs＆Co.LLC）和罗斯柴尔德公司（Rothschild＆Co.）担任财务顾问，古德温·普罗科特律师事务所（Goodwin Procter LLP）和里德史密斯律师事务所（ReedSmith LLP）担任RCA的法律顾问。

About Cencora

关于Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.

Cencora是一家领先的全球制药解决方案组织，致力于改善世界各地人和动物的生活。Cencora与整个价值链上的药物创新者合作，以促进和优化治疗的市场准入。护理提供者依靠Cencora安全可靠地提供药品、保健产品和解决方案。

Cencora’s 46,000+ worldwide team members contribute to positive health outcomes through the power of Cencora’s purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500 with more than $290 billion in annual revenue.

Cencora的46000多名全球团队成员通过Cencora宗旨的力量为积极的健康结果做出贡献：Cencora团结一致，共同创造更健康的未来。Cencora在财富500强中排名第10位，在全球财富500强中排名第24位，年收入超过2900亿美元。

Learn more at investor.cencora.com..

有关详细信息，请访问investor.cencora.com。

About Webster Equity Partners

关于Webster Equity Partners

Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for its investors, portfolio companies and the communities that it serves. Its mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients.

韦伯斯特成立于2003年，是一家专注于高影响力增长战略的私人股本公司，旨在为其投资者、投资组合公司及其服务的社区提供最佳结果。它的使命是通过投资和发展以目标为导向的以患者为中心的医疗保健组织，为我们的合作伙伴提供优异的回报，这些组织致力于为患者提供一流的临床护理和服务。

(https://websterequitypartners.com/).

（轻笑）https://websterequitypartners.com/).

Cencora’s Cautionary Note Regarding Forward-Looking Statements

Cencora关于前瞻性声明的警示说明

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Such forward-looking statements may include, without limitation, statements about the proposed transaction with RCA, the expected timetable for completing the proposed transaction, the benefits of the proposed transaction, future opportunities for Cencora and RCA and any other statements regarding Cencora’s or RCA’s future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, and other expectations for future periods.

本新闻稿中的某些声明是《1933年证券法》（经修订）第27A节和《1934年证券交易法》（经修订）第21E节所指的“前瞻性声明”。此类前瞻性陈述可能包括但不限于关于与RCA拟议交易的陈述、完成拟议交易的预期时间表、拟议交易的好处、Cencora和RCA的未来机会，以及关于Cencora或RCA未来运营、财务或运营业绩、预期业务水平、未来收益、计划活动、预期增长、市场机会、战略和未来时期其他预期的任何其他陈述。

Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,”, “estimate,” 'expect,' “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

诸如“目标”，“预期”，“相信”，“可以”，“继续”，“可以”，“估计”，“预期”，“打算”，“可能”，“可能”，“正在轨道上”，“机会”，“计划”，“可能”，“潜在”，“预测”，“项目”，“寻求”，“应该”，“努力”，“维持”，“协同作用”，“目标”，“将会”，“将会”和类似的表达都是为了识别前瞻性陈述，但没有这些词并不意味着陈述不是前瞻性的。

Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties’ ability to meet expectations regarding the timing of the proposed transaction; the parties’ ability to consummate the proposed transaction; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the antici.

由于前瞻性陈述固有地涉及风险和不确定性，因此实际的未来结果可能与此类前瞻性陈述所表达或暗示的结果存在重大差异。可能导致或促成此类差异的因素包括但不限于：各方满足拟议交易时间预期的能力；；拟议交易所需的监管批准未按预期条款或antici获得。

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities of Cencora. Any such offer will only be made pursuant to a prospectus filed with the SEC or pursuant to one or more exemptions from the registration requirements of the Securities Act of 1933, as amended..

本新闻稿既不是出售要约，也不是购买Cencora任何证券的要约。任何此类要约只能根据向美国证券交易委员会提交的招股说明书或根据1933年《证券法》修订版的一项或多项豁免注册要求进行。

Supplemental Information Regarding Non-GAAP Financial Measure

关于非GAAP财务指标的补充信息

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), Cencora uses the non-GAAP financial measure described below. The non-GAAP financial measure should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP.

为了补充根据美国公认会计原则（GAAP）编制的财务指标，Cencora使用了下文所述的非GAAP财务指标。非GAAP财务指标应作为根据GAAP计算的财务指标的补充，而不是替代。

This supplemental measure may vary from, and may not be comparable to, similarly titled measures by other companies..

此补充措施可能与其他公司的类似标题措施有所不同，也可能无法与之进行比较。

The non-GAAP financial measure is presented because Cencora’s management uses non-GAAP financial measures to evaluate Cencora’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, Cencora believes that the presentation of the non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors.

之所以提出非公认会计准则财务指标，是因为Cencora管理层使用非公认会计准则财务指标来评估Cencora的经营业绩、执行财务规划和确定激励薪酬。因此，Cencora认为，非公认会计准则财务指标的列报为投资者提供了有用的补充信息，并有助于投资者进行进一步分析。

The presented non-GAAP financial measure excludes items that management does not believe reflect Cencora’s core operating performance because such items are outside the control of Cencora or are inherently unusual, non-operating, unpredictable, non-recurring, or non-cash..

所提出的非GAAP财务指标不包括管理层认为不反映Cencora核心经营业绩的项目，因为这些项目不在Cencora的控制范围内，或者本质上是异常的、非经营性的、不可预测的、非经常性的或非现金的。

Cencora does not provide a reconciliation for this non-GAAP financial measure on a forward-looking basis to the most comparable GAAP financial measure on a forward-looking basis because it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort due to the uncertainty and potential variability of reconciling items, which are dependent on future events, are out of Cencora’s control and/or cannot be reasonably predicted, and the probable significance of which cannot be determined..

Cencora不提供该非GAAP财务指标与最具可比性的GAAP财务指标的前瞻性对账，因为它无法对对账项目进行有意义或准确的计算或估计，并且由于对账项目的不确定性和潜在可变性（取决于未来事件）超出Cencora的控制和/或无法合理预测，并且无法确定其可能的重要性，因此如果不付出不合理的努力，信息就不可用。

This press release includes adjusted diluted earnings per share (“EPS”), which represents diluted earnings per share determined in accordance with GAAP adjusted for specific items, including the per share impact of: gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-related intangibles amortization; litigation and opioid expenses (credit); acquisition-related deal and integration expenses; restructuring and other expenses; impairment of goodwill; the gain on the divestiture of non-core businesses; the gain (loss) on the currency remeasurement related to 2020 Swiss tax reform; and the gain (loss) on the remeasurement of an equity investment, in each case net of the tax effect calculated using the applicable effective tax rate for those items.

本新闻稿包括调整后的稀释每股收益（“EPS”），它代表根据GAAP确定的稀释每股收益，针对特定项目进行了调整，包括每股影响：反垄断诉讼和解收益；土耳其通货膨胀率高；后进先出费用（信贷）；收购相关无形资产摊销；；收购相关交易和整合费用；重组和其他费用；商誉减值；非核心业务剥离的收益；与2020年瑞士税收改革相关的货币重新计量收益（损失）；以及重新计量股权投资的收益（损失），在每种情况下，均扣除使用这些项目的适用有效税率计算的税收影响。

In addition, the per share impact of certain discrete tax items primarily attributable to an adjustment of a foreign valuation allowance, and the per share impact of certain expenses related to 2020 Swiss tax reform are also excluded from adjusted diluted earnings per share. Cencora’s management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of items that are outside the control of Cencora that are not considered to be indicative of ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature..

此外，调整后的稀释每股收益也不包括主要归因于外国估值备抵调整的某些离散税项的每股影响，以及与2020年瑞士税制改革相关的某些费用的每股影响。Cencora管理层认为，这一非公认会计准则财务指标对投资者很有用，因为它消除了Cencora无法控制的项目的每股影响，这些项目由于其固有的异常、非经营性、不可预测性、非经常性或非现金性质而不被视为持续经营业绩的指标。